Tecentriq Hybreza™ (atezolizumab/hyaluronidase-tqjs) – New subcutaneous formulation approval
September 12, 2024 - Roche announced the FDA approval of Tecentriq Hybreza (atezolizumab/hyaluronidase-tqjs), for all intravenous (IV) indications of Tecentriq® (atezolizumab) approved for adults, including certain types of lung, liver, skin and soft tissue cancer.
Top